Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001735276-24-000104
Filing Date
2024-11-27
Accepted
2024-11-27 17:20:36
Documents
1
Period of Report
2024-11-25

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT edgardoc.html 4  
1 PRIMARY DOCUMENT edgardoc.xml 4 21306
  Complete submission text file 0001735276-24-000104.txt   22912
Mailing Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142
Business Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Issuer) CIK: 0001178670 (see all company filings)

EIN.: 770602661 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O OVID THERAPEUTICS INC. 1460 BROADWAY, SUITE 15044 NEW YORK NY 10036
Business Address
Fitzgerald Kevin Joseph (Reporting) CIK: 0001886431 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36407 | Film No.: 241512466